Interim data from the open-label phase 3 MagnetisMM-32 study demonstrate a significant progression free survival benefit with elranatamab monotherapy vs active standard regimens in patients previously ...

Topline phase 3 data show tradipitant significantly reduced semaglutide-associated vomiting and severe nausea in adults with overweight or obesity.

HealthDay News — Dengue cases in Florida keep climbing about a month after 3 counties declared states of emergency over the ...

HealthDay News — More than half of children younger than 5 years exposed to hepatitis B virus (HBV) are exposed by someone in their household other than their birth mother, according to a study ...

HealthDay News — Treating depression with interpersonal psychotherapy during pregnancy influences infant brain development and early emotional function, according to a study published online October ...

All PROs significantly higher for those discontinuing TNFi at week 12 vs week 0, but not at later time points.

Compared with the placebo group, the 400mg group had significantly higher percentages of participants with clinical remission ...

HealthDay News — For patients with atrial fibrillation (AF) and prior intracranial bleeding, direct oral anticoagulants (DOACs) are associated with a reduced risk for ischemic stroke (IS) and death, ...

Adults with moderately to severely active Crohn disease can now self-administer risankizumab induction at home using an ...

HealthDay News — Early uptake was rapid for oral semaglutide (Wegovy pill) relative to injectable incretin-based weight ...

HealthDay News — Medical device adverse event reports are frequently incomplete, inaccurate, and delayed, according to a study published online October 14 in The BMJ.

Mean percentage of time that CGM-measured glucose level was in range of 70 to 180mg/dL was 21 percentage points higher with ...